Aligos Therapeutics Inc (ALGS)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$4.78-0.83%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Aligos Therapeutics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	537,500
EPS	—	-1.917
Annual ending 2026-12-31
Revenue	—	35.99M
EPS	—	-6.554
Annual ending 2027-12-31
Revenue	—	4.07M
EPS	—	-5.374

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain sufficient cash to fund operations into late 2026	Management aims to maintain cash to fund operations into late 2026.	Intact	cash burn accelerates and funding runs out before late 2026	Cash from operations: $-24.95M FY2026-Q2; GAAP. Published target: cash and investments sufficient to fund operations through Q4 2026. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-24,950,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 4 quarters from 2025-Q2 through 2026-Q2. Cash, cash equivalents and investments declined from $77.8M at end 2025 to $30.4M at 2026-Q2, excluding the $25M upfront payment received in July 2026. Management consistently affirms funding sufficiency into late 2026, reflecting mixed progress due to cash burn but supported by milestone payments. Delivery assessment Oct 24, 2026
Advance clinical development of pevifoscorvir sodium	These show progress in clinical and commercial development despite losses.	Improving	clinical development progress stalls or regresses in 2026	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 disclosures including 2026-Q1 and 2026-Q2 press releases and a 2026-04 announcement. The Phase 2 B-SUPREME study enrollment increased to 245 participants across cohorts, with topline data expected in late Q3 2027. Management has consistently emphasized progress including FDA Fast Track and Breakthrough Designations, indicating delivering trajectory on clinical development. Delivery assessment Oct 24, 2026
Increase revenue through clinical and commercial progress	These show progress in clinical and commercial development despite losses.	Intact	YoY revenue growth falls below 4% next year	Revenue: $27.778M FY2026-Q2; GAAP. Published target: sustain revenue growth above 4% annually. Target and observation units differ. Source published Aug 6, 202627,778,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 3 quarters including 2025-Q4, 2026-Q1, and 2026-Q2. Revenue increased from $169K in 2025-Q4 to $2.83M in 2026-Q2, driven by $27.8M licensing revenue from the Amoytop deal and a $3M milestone payment. Management's emphasis on revenue growth through clinical and commercial progress is supported by these new revenue streams, indicating delivering trajectory. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-5.37

$-3.99 → $-5.37 · observed estimates

FY2027 revenue$0.00B

$0.01B → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-3.99	$5,000,000	6 / 6
2026-07-25	$-3.99	$5,000,000	6 / 6
2026-07-26	$-3.99	$5,000,000	6 / 6
2026-07-27	$-3.99	$5,000,000	6 / 6
2026-07-28	$-3.99	$5,000,000	6 / 6
2026-07-29	$-3.99	$5,000,000	6 / 6
2026-07-30	$-3.99	$5,000,000	6 / 6
2026-07-31	$-3.99	$5,000,000	6 / 6
2026-08-01	$-3.99	$5,000,000	6 / 6
2026-08-02	$-3.99	$5,000,000	6 / 6
2026-08-03	$-3.99	$5,000,000	6 / 6
2026-08-04	$-3.99	$5,000,000	6 / 6
2026-08-05	$-3.99	$5,000,000	6 / 6
2026-08-06	$-3.99	$5,000,000	6 / 6
2026-08-07	$-4.48	Unavailable	5 / 4
2026-08-08	$-3.99	$5,000,000	6 / 6
2026-08-09	$-3.99	$5,000,000	6 / 6
2026-08-10	$-3.99	$5,000,000	6 / 6
2026-08-11	$-4.98	Unavailable	6 / 4
2026-08-12	$-5.05	$5,425,000	6 / 6
2026-08-13	$-5.05	$5,425,000	6 / 6
2026-08-14	$-4.48	Unavailable	5 / 4
2026-08-15	$-4.48	Unavailable	5 / 4
2026-08-16	$-4.48	Unavailable	5 / 4
2026-08-17	$-4.48	Unavailable	5 / 4
2026-08-18	$-4.48	Unavailable	5 / 4
2026-08-19	$-4.48	Unavailable	5 / 4
2026-08-20	$-5.18	Unavailable	5 / 4
2026-08-21	$-5.18	Unavailable	5 / 4
2026-08-22	$-5.18	Unavailable	5 / 4
2026-08-23	$-5.18	Unavailable	5 / 4
2026-08-24	$-5.18	Unavailable	5 / 4
2026-08-25	$-5.18	Unavailable	5 / 4
2026-08-26	$-5.18	Unavailable	5 / 4
2026-08-27	$-5.18	Unavailable	5 / 4
2026-08-28	$-5.18	Unavailable	5 / 4
2026-08-29	$-5.18	Unavailable	5 / 4
2026-08-30	$-5.18	Unavailable	5 / 4
2026-08-31	$-5.18	Unavailable	5 / 4
2026-09-01	$-5.18	Unavailable	5 / 4
2026-09-02	$-5.18	Unavailable	5 / 4
2026-09-03	$-5.18	Unavailable	5 / 4
2026-09-04	$-5.18	Unavailable	5 / 4
2026-09-05	$-5.18	Unavailable	5 / 4
2026-09-06	$-5.18	Unavailable	5 / 4
2026-09-07	$-5.18	Unavailable	5 / 4
2026-09-08	$-5.18	Unavailable	5 / 4
2026-09-09	$-5.18	Unavailable	5 / 4
2026-09-10	$-5.18	Unavailable	5 / 4
2026-09-11	$-5.18	Unavailable	5 / 4
2026-09-12	$-5.18	Unavailable	5 / 4
2026-09-13	$-5.18	Unavailable	5 / 4
2026-09-14	$-5.18	Unavailable	5 / 4
2026-09-15	$-5.18	Unavailable	5 / 4
2026-09-16	$-5.18	$4,068,749	6 / 5
2026-09-17	$-5.18	$4,068,749	6 / 5
2026-09-18	$-5.18	$4,068,749	6 / 5
2026-09-19	$-5.18	$4,068,749	6 / 5
2026-09-20	$-5.18	$4,068,749	6 / 5
2026-09-21	$-5.18	$4,068,749	6 / 5
2026-09-22	$-5.18	$4,068,749	6 / 5
2026-09-23	$-5.18	$4,068,749	6 / 5
2026-09-24	$-5.18	$4,068,749	6 / 5
2026-09-25	$-5.18	$4,068,749	6 / 5
2026-09-26	$-5.18	$4,068,749	6 / 5
2026-09-27	$-5.18	$4,068,749	6 / 5
2026-09-28	$-5.18	$4,068,749	6 / 5
2026-09-29	$-5.18	$4,068,749	6 / 5
2026-09-30	$-5.18	$4,068,749	6 / 5
2026-10-01	$-5.18	$4,068,749	6 / 5
2026-10-02	$-5.18	$4,068,749	6 / 5
2026-10-03	$-5.18	$4,068,749	6 / 5
2026-10-04	$-5.18	$4,068,749	6 / 5
2026-10-05	$-5.18	$4,068,749	6 / 5
2026-10-06	$-5.18	$4,068,749	6 / 5
2026-10-07	$-5.18	$4,068,749	6 / 5
2026-10-08	$-5.18	$4,068,749	6 / 5
2026-10-09	$-5.18	$4,068,749	6 / 5
2026-10-10	$-5.18	$4,068,749	6 / 5
2026-10-11	$-5.18	$4,068,749	6 / 5
2026-10-12	$-5.18	$4,068,749	6 / 5
2026-10-13	$-5.18	$4,068,749	6 / 5
2026-10-14	$-5.18	$4,068,749	6 / 5
2026-10-15	$-5.18	$4,068,749	6 / 5
2026-10-16	$-5.18	$4,068,749	6 / 5
2026-10-17	$-5.18	$4,068,749	6 / 5
2026-10-18	$-5.18	$4,068,749	6 / 5
2026-10-19	$-5.18	$4,068,749	6 / 5
2026-10-20	$-5.18	$4,068,749	6 / 5
2026-10-21	$-5.18	$4,068,749	6 / 5
2026-10-22	$-5.18	$4,068,749	6 / 5
2026-10-23	$-5.18	$4,068,749	6 / 5
2026-10-24	$-5.37	$4,068,749	6 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	7	0	0
2026-06-01	8	0	0
2026-07-01	8	0	0
2026-08-01	8	0	0
2026-09-01	8	0	0
2026-10-01	8	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 8 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain sufficient cash to fund operations into late 2026Cash from operations: $-24.95M
Advance clinical development of pevifoscorvir sodiumQualitative condition
Increase revenue through clinical and commercial progressRevenue: $27.778M

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.5%Typical daily move · historical

Downside history

-69.3%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Aligos Therapeutics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-stage healthcare business, not a profitable compounder today. The long-term thesis remains intact, with management advancing its lead program, but the evidence is mixed and the risk level is high.

What's priced into Aligos Therapeutics Inc

The valuation model places ALGS at a 16% premium to peers, and the expectations gap is negative, meaning expectations appear demanding relative to the evidence. The priced-in signal is tagged as justified, with no fragility gates triggered, but confidence in that assessment is medium.

What the fundamentals likely do

Near term, recent results have been neutral overall, despite earnings beats in May and August and higher reported revenue in the second quarter, including licensing and milestone payments. Management is on track with clinical development, but cash and investments fell to $30.4 million by the end of the second quarter, excluding a later $25 million upfront payment; funding is stated to extend into late 2026. The next results carry meaningful execution risk, and a guidance cut would be a negative signal.

What Aligos Therapeutics Inc hinges on

The multi-year view depends on progress in the Phase 2 B-SUPREME study, which enrolled 245 participants, with topline data expected in late Q3 2027. Near term, the key swing factors are guidance, cash use, and whether weakening jobs data raises recession concerns for cyclical healthcare names. Continued strength from healthcare bellwethers could support sector momentum, though that is not specific proof of ALGS's business progress.